Antitumour activity of [1,2-di(cyclopentadienyl)-1,2-di( p- N, N-dimethylaminophenyl)-ethanediyl] titanium dichloride in xenografted Ehrlich's ascites tumour

The effects of a new titanocene compound with an ansa ligand in the cyclopentadienyl rings, the 1,2-di(cyclopentadienyl)-1,2-di( p- N, N-dimethylaminophenyl)-ethanediyl] titanium dichloride (TITANOCENE X), on the growth and differentiation of granulocyte–macrophage progenitor cells [colony-forming u...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:European journal of pharmacology 2006-03, Vol.534 (1), p.264-270
Hauptverfasser: Valadares, Marize C., Ramos, Aline L., Rehmann, Franz-Josef K., Sweeney, Nigel J., Strohfeldt, Katja, Tacke, Matthias, Queiroz, Mary L.S.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 270
container_issue 1
container_start_page 264
container_title European journal of pharmacology
container_volume 534
creator Valadares, Marize C.
Ramos, Aline L.
Rehmann, Franz-Josef K.
Sweeney, Nigel J.
Strohfeldt, Katja
Tacke, Matthias
Queiroz, Mary L.S.
description The effects of a new titanocene compound with an ansa ligand in the cyclopentadienyl rings, the 1,2-di(cyclopentadienyl)-1,2-di( p- N, N-dimethylaminophenyl)-ethanediyl] titanium dichloride (TITANOCENE X), on the growth and differentiation of granulocyte–macrophage progenitor cells [colony-forming unit-granulocyte–macrophage (CFU-GM)] and Natural killer (NK) cell activity in Ehrlich's ascites tumour (EAT)-bearing mice were studied. Myelosuppression concomitant with increased numbers of spleen CFU-GM was observed in tumour-bearing mice. Treatment of these animals with TITANOCENE X (2.5–50 mg/kg/day) produced an increase in myelopoiesis, in a dose-dependent manner, and reduced spleen colony formation. In addition, the treatment of EAT-bearing mice with 3 doses of 20 or 50 mg/kg TITANOCENE X restored to normal values the reduced Natural killer cell function observed during tumour growth. In parallel, TITANOCENE X prolonged, in a dose-dependent manner, the survival of mice inoculated with Ehrlich's ascites tumour. The highest dose of 50 mg/kg prolonged in 50% the survival time of EAT-bearing mice, compared to non-treated tumour-bearing controls. In comparison with previous results from our laboratory addressing the effects of titanocenes on haematopoiesis, we observed with TITANOCENE X a similar effective profile as for bis(cyclopentadienyl) dithiocyanate titanium(IV), being both less effective than di(cyclopentadienyl) dichloro titanium(IV), since the latter not only prolonged, but also increased the rate of survival. These differences in efficacy may be due to the nature of the ansa-cyclopentadienyl ligand used in TITANOCENE X, since the C 2 bridge between the two cyclopentadienyl groups will increase the hydrolytic stability by an organometallic chelate effect. Also, the introduction of two dimethylamino substituents increases the water solubility of TITANOCENE X when compared to titanocene dichloride itself.
doi_str_mv 10.1016/j.ejphar.2006.01.056
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_67735874</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0014299906000884</els_id><sourcerecordid>67735874</sourcerecordid><originalsourceid>FETCH-LOGICAL-c390t-1d9531ee3710d1bb8d560bea7986f330e42d369ccbbd7d0b2bc2af3cc25a66813</originalsourceid><addsrcrecordid>eNp9kctq3jAQhU1paf6kfYNStOkNYleSLdneFEJILxDSTbsqRcjSuNaPbDmSHOqHybtWwYbsuhox881hdE6WvSK4IJjwj8cCjvMgfUEx5gUmBWb8SXYgTd3muCb0aXbAmFQ5bdv2JDsN4YgxZi1lz7MTwhkpCeaH7P5iiiYuo1s8kiqaOxNX5Hr0i5zTXJv3alXWzTBFqQ1Mq_2Q7wM05-jmHN2k9whxWK0czeTmYYNSR06gzWp_o6QvJ7OMSBs1WOeNBmQm9Bcm98fLPoJGV4O3afguIBmUiRDQdtKL7FkvbYCXez3Lfn6--nH5Nb_-_uXb5cV1rsoWx5zolpUEoKwJ1qTrGs047kDWbcP7ssRQUV3yVqmu07XGHe0UlX2pFGWS84aUZ9nbTXf27naBEMVoggJr0yfcEgSv65I1dZXAagOVdyF46MXszSj9KggWD7GIo9hiEQ-xCExEiiWtvd71l24E_bi055CANzuQDJC293JSJjxyNWsorVjiPm0cJDfuDHiR_IJJJas9qCi0M_-_5B-Ela91</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>67735874</pqid></control><display><type>article</type><title>Antitumour activity of [1,2-di(cyclopentadienyl)-1,2-di( p- N, N-dimethylaminophenyl)-ethanediyl] titanium dichloride in xenografted Ehrlich's ascites tumour</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Valadares, Marize C. ; Ramos, Aline L. ; Rehmann, Franz-Josef K. ; Sweeney, Nigel J. ; Strohfeldt, Katja ; Tacke, Matthias ; Queiroz, Mary L.S.</creator><creatorcontrib>Valadares, Marize C. ; Ramos, Aline L. ; Rehmann, Franz-Josef K. ; Sweeney, Nigel J. ; Strohfeldt, Katja ; Tacke, Matthias ; Queiroz, Mary L.S.</creatorcontrib><description>The effects of a new titanocene compound with an ansa ligand in the cyclopentadienyl rings, the 1,2-di(cyclopentadienyl)-1,2-di( p- N, N-dimethylaminophenyl)-ethanediyl] titanium dichloride (TITANOCENE X), on the growth and differentiation of granulocyte–macrophage progenitor cells [colony-forming unit-granulocyte–macrophage (CFU-GM)] and Natural killer (NK) cell activity in Ehrlich's ascites tumour (EAT)-bearing mice were studied. Myelosuppression concomitant with increased numbers of spleen CFU-GM was observed in tumour-bearing mice. Treatment of these animals with TITANOCENE X (2.5–50 mg/kg/day) produced an increase in myelopoiesis, in a dose-dependent manner, and reduced spleen colony formation. In addition, the treatment of EAT-bearing mice with 3 doses of 20 or 50 mg/kg TITANOCENE X restored to normal values the reduced Natural killer cell function observed during tumour growth. In parallel, TITANOCENE X prolonged, in a dose-dependent manner, the survival of mice inoculated with Ehrlich's ascites tumour. The highest dose of 50 mg/kg prolonged in 50% the survival time of EAT-bearing mice, compared to non-treated tumour-bearing controls. In comparison with previous results from our laboratory addressing the effects of titanocenes on haematopoiesis, we observed with TITANOCENE X a similar effective profile as for bis(cyclopentadienyl) dithiocyanate titanium(IV), being both less effective than di(cyclopentadienyl) dichloro titanium(IV), since the latter not only prolonged, but also increased the rate of survival. These differences in efficacy may be due to the nature of the ansa-cyclopentadienyl ligand used in TITANOCENE X, since the C 2 bridge between the two cyclopentadienyl groups will increase the hydrolytic stability by an organometallic chelate effect. Also, the introduction of two dimethylamino substituents increases the water solubility of TITANOCENE X when compared to titanocene dichloride itself.</description><identifier>ISSN: 0014-2999</identifier><identifier>EISSN: 1879-0712</identifier><identifier>DOI: 10.1016/j.ejphar.2006.01.056</identifier><identifier>PMID: 16513106</identifier><identifier>CODEN: EJPHAZ</identifier><language>eng</language><publisher>Amsterdam: Elsevier B.V</publisher><subject>Abdomen ; Animals ; Antineoplastic Agents - pharmacology ; Antineoplastic Agents - therapeutic use ; Biological and medical sciences ; Carcinoma, Ehrlich Tumor - drug therapy ; Carcinoma, Ehrlich Tumor - immunology ; Carcinoma, Ehrlich Tumor - pathology ; Cell Proliferation ; Colony-Forming Units Assay ; Dose-Response Relationship, Drug ; Gastroenterology. Liver. Pancreas. Abdomen ; Haematopoiesis ; Hematopoietic Stem Cells - drug effects ; Hematopoietic Stem Cells - pathology ; Killer Cells, Natural - drug effects ; Killer Cells, Natural - immunology ; Male ; Medical sciences ; Mice ; Mice, Inbred BALB C ; Myelopoiesis - drug effects ; Natural killer ; Neoplasm Transplantation ; Organometallic Compounds - pharmacology ; Organometallic Compounds - therapeutic use ; Other diseases. Semiology ; Pharmacology. Drug treatments ; Titanocene ; Tumour</subject><ispartof>European journal of pharmacology, 2006-03, Vol.534 (1), p.264-270</ispartof><rights>2006 Elsevier B.V.</rights><rights>2006 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c390t-1d9531ee3710d1bb8d560bea7986f330e42d369ccbbd7d0b2bc2af3cc25a66813</citedby><cites>FETCH-LOGICAL-c390t-1d9531ee3710d1bb8d560bea7986f330e42d369ccbbd7d0b2bc2af3cc25a66813</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0014299906000884$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=17582245$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16513106$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Valadares, Marize C.</creatorcontrib><creatorcontrib>Ramos, Aline L.</creatorcontrib><creatorcontrib>Rehmann, Franz-Josef K.</creatorcontrib><creatorcontrib>Sweeney, Nigel J.</creatorcontrib><creatorcontrib>Strohfeldt, Katja</creatorcontrib><creatorcontrib>Tacke, Matthias</creatorcontrib><creatorcontrib>Queiroz, Mary L.S.</creatorcontrib><title>Antitumour activity of [1,2-di(cyclopentadienyl)-1,2-di( p- N, N-dimethylaminophenyl)-ethanediyl] titanium dichloride in xenografted Ehrlich's ascites tumour</title><title>European journal of pharmacology</title><addtitle>Eur J Pharmacol</addtitle><description>The effects of a new titanocene compound with an ansa ligand in the cyclopentadienyl rings, the 1,2-di(cyclopentadienyl)-1,2-di( p- N, N-dimethylaminophenyl)-ethanediyl] titanium dichloride (TITANOCENE X), on the growth and differentiation of granulocyte–macrophage progenitor cells [colony-forming unit-granulocyte–macrophage (CFU-GM)] and Natural killer (NK) cell activity in Ehrlich's ascites tumour (EAT)-bearing mice were studied. Myelosuppression concomitant with increased numbers of spleen CFU-GM was observed in tumour-bearing mice. Treatment of these animals with TITANOCENE X (2.5–50 mg/kg/day) produced an increase in myelopoiesis, in a dose-dependent manner, and reduced spleen colony formation. In addition, the treatment of EAT-bearing mice with 3 doses of 20 or 50 mg/kg TITANOCENE X restored to normal values the reduced Natural killer cell function observed during tumour growth. In parallel, TITANOCENE X prolonged, in a dose-dependent manner, the survival of mice inoculated with Ehrlich's ascites tumour. The highest dose of 50 mg/kg prolonged in 50% the survival time of EAT-bearing mice, compared to non-treated tumour-bearing controls. In comparison with previous results from our laboratory addressing the effects of titanocenes on haematopoiesis, we observed with TITANOCENE X a similar effective profile as for bis(cyclopentadienyl) dithiocyanate titanium(IV), being both less effective than di(cyclopentadienyl) dichloro titanium(IV), since the latter not only prolonged, but also increased the rate of survival. These differences in efficacy may be due to the nature of the ansa-cyclopentadienyl ligand used in TITANOCENE X, since the C 2 bridge between the two cyclopentadienyl groups will increase the hydrolytic stability by an organometallic chelate effect. Also, the introduction of two dimethylamino substituents increases the water solubility of TITANOCENE X when compared to titanocene dichloride itself.</description><subject>Abdomen</subject><subject>Animals</subject><subject>Antineoplastic Agents - pharmacology</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Carcinoma, Ehrlich Tumor - drug therapy</subject><subject>Carcinoma, Ehrlich Tumor - immunology</subject><subject>Carcinoma, Ehrlich Tumor - pathology</subject><subject>Cell Proliferation</subject><subject>Colony-Forming Units Assay</subject><subject>Dose-Response Relationship, Drug</subject><subject>Gastroenterology. Liver. Pancreas. Abdomen</subject><subject>Haematopoiesis</subject><subject>Hematopoietic Stem Cells - drug effects</subject><subject>Hematopoietic Stem Cells - pathology</subject><subject>Killer Cells, Natural - drug effects</subject><subject>Killer Cells, Natural - immunology</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Mice</subject><subject>Mice, Inbred BALB C</subject><subject>Myelopoiesis - drug effects</subject><subject>Natural killer</subject><subject>Neoplasm Transplantation</subject><subject>Organometallic Compounds - pharmacology</subject><subject>Organometallic Compounds - therapeutic use</subject><subject>Other diseases. Semiology</subject><subject>Pharmacology. Drug treatments</subject><subject>Titanocene</subject><subject>Tumour</subject><issn>0014-2999</issn><issn>1879-0712</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kctq3jAQhU1paf6kfYNStOkNYleSLdneFEJILxDSTbsqRcjSuNaPbDmSHOqHybtWwYbsuhox881hdE6WvSK4IJjwj8cCjvMgfUEx5gUmBWb8SXYgTd3muCb0aXbAmFQ5bdv2JDsN4YgxZi1lz7MTwhkpCeaH7P5iiiYuo1s8kiqaOxNX5Hr0i5zTXJv3alXWzTBFqQ1Mq_2Q7wM05-jmHN2k9whxWK0czeTmYYNSR06gzWp_o6QvJ7OMSBs1WOeNBmQm9Bcm98fLPoJGV4O3afguIBmUiRDQdtKL7FkvbYCXez3Lfn6--nH5Nb_-_uXb5cV1rsoWx5zolpUEoKwJ1qTrGs047kDWbcP7ssRQUV3yVqmu07XGHe0UlX2pFGWS84aUZ9nbTXf27naBEMVoggJr0yfcEgSv65I1dZXAagOVdyF46MXszSj9KggWD7GIo9hiEQ-xCExEiiWtvd71l24E_bi055CANzuQDJC293JSJjxyNWsorVjiPm0cJDfuDHiR_IJJJas9qCi0M_-_5B-Ela91</recordid><startdate>20060318</startdate><enddate>20060318</enddate><creator>Valadares, Marize C.</creator><creator>Ramos, Aline L.</creator><creator>Rehmann, Franz-Josef K.</creator><creator>Sweeney, Nigel J.</creator><creator>Strohfeldt, Katja</creator><creator>Tacke, Matthias</creator><creator>Queiroz, Mary L.S.</creator><general>Elsevier B.V</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20060318</creationdate><title>Antitumour activity of [1,2-di(cyclopentadienyl)-1,2-di( p- N, N-dimethylaminophenyl)-ethanediyl] titanium dichloride in xenografted Ehrlich's ascites tumour</title><author>Valadares, Marize C. ; Ramos, Aline L. ; Rehmann, Franz-Josef K. ; Sweeney, Nigel J. ; Strohfeldt, Katja ; Tacke, Matthias ; Queiroz, Mary L.S.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c390t-1d9531ee3710d1bb8d560bea7986f330e42d369ccbbd7d0b2bc2af3cc25a66813</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Abdomen</topic><topic>Animals</topic><topic>Antineoplastic Agents - pharmacology</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Carcinoma, Ehrlich Tumor - drug therapy</topic><topic>Carcinoma, Ehrlich Tumor - immunology</topic><topic>Carcinoma, Ehrlich Tumor - pathology</topic><topic>Cell Proliferation</topic><topic>Colony-Forming Units Assay</topic><topic>Dose-Response Relationship, Drug</topic><topic>Gastroenterology. Liver. Pancreas. Abdomen</topic><topic>Haematopoiesis</topic><topic>Hematopoietic Stem Cells - drug effects</topic><topic>Hematopoietic Stem Cells - pathology</topic><topic>Killer Cells, Natural - drug effects</topic><topic>Killer Cells, Natural - immunology</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Mice</topic><topic>Mice, Inbred BALB C</topic><topic>Myelopoiesis - drug effects</topic><topic>Natural killer</topic><topic>Neoplasm Transplantation</topic><topic>Organometallic Compounds - pharmacology</topic><topic>Organometallic Compounds - therapeutic use</topic><topic>Other diseases. Semiology</topic><topic>Pharmacology. Drug treatments</topic><topic>Titanocene</topic><topic>Tumour</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Valadares, Marize C.</creatorcontrib><creatorcontrib>Ramos, Aline L.</creatorcontrib><creatorcontrib>Rehmann, Franz-Josef K.</creatorcontrib><creatorcontrib>Sweeney, Nigel J.</creatorcontrib><creatorcontrib>Strohfeldt, Katja</creatorcontrib><creatorcontrib>Tacke, Matthias</creatorcontrib><creatorcontrib>Queiroz, Mary L.S.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Valadares, Marize C.</au><au>Ramos, Aline L.</au><au>Rehmann, Franz-Josef K.</au><au>Sweeney, Nigel J.</au><au>Strohfeldt, Katja</au><au>Tacke, Matthias</au><au>Queiroz, Mary L.S.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Antitumour activity of [1,2-di(cyclopentadienyl)-1,2-di( p- N, N-dimethylaminophenyl)-ethanediyl] titanium dichloride in xenografted Ehrlich's ascites tumour</atitle><jtitle>European journal of pharmacology</jtitle><addtitle>Eur J Pharmacol</addtitle><date>2006-03-18</date><risdate>2006</risdate><volume>534</volume><issue>1</issue><spage>264</spage><epage>270</epage><pages>264-270</pages><issn>0014-2999</issn><eissn>1879-0712</eissn><coden>EJPHAZ</coden><abstract>The effects of a new titanocene compound with an ansa ligand in the cyclopentadienyl rings, the 1,2-di(cyclopentadienyl)-1,2-di( p- N, N-dimethylaminophenyl)-ethanediyl] titanium dichloride (TITANOCENE X), on the growth and differentiation of granulocyte–macrophage progenitor cells [colony-forming unit-granulocyte–macrophage (CFU-GM)] and Natural killer (NK) cell activity in Ehrlich's ascites tumour (EAT)-bearing mice were studied. Myelosuppression concomitant with increased numbers of spleen CFU-GM was observed in tumour-bearing mice. Treatment of these animals with TITANOCENE X (2.5–50 mg/kg/day) produced an increase in myelopoiesis, in a dose-dependent manner, and reduced spleen colony formation. In addition, the treatment of EAT-bearing mice with 3 doses of 20 or 50 mg/kg TITANOCENE X restored to normal values the reduced Natural killer cell function observed during tumour growth. In parallel, TITANOCENE X prolonged, in a dose-dependent manner, the survival of mice inoculated with Ehrlich's ascites tumour. The highest dose of 50 mg/kg prolonged in 50% the survival time of EAT-bearing mice, compared to non-treated tumour-bearing controls. In comparison with previous results from our laboratory addressing the effects of titanocenes on haematopoiesis, we observed with TITANOCENE X a similar effective profile as for bis(cyclopentadienyl) dithiocyanate titanium(IV), being both less effective than di(cyclopentadienyl) dichloro titanium(IV), since the latter not only prolonged, but also increased the rate of survival. These differences in efficacy may be due to the nature of the ansa-cyclopentadienyl ligand used in TITANOCENE X, since the C 2 bridge between the two cyclopentadienyl groups will increase the hydrolytic stability by an organometallic chelate effect. Also, the introduction of two dimethylamino substituents increases the water solubility of TITANOCENE X when compared to titanocene dichloride itself.</abstract><cop>Amsterdam</cop><pub>Elsevier B.V</pub><pmid>16513106</pmid><doi>10.1016/j.ejphar.2006.01.056</doi><tpages>7</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0014-2999
ispartof European journal of pharmacology, 2006-03, Vol.534 (1), p.264-270
issn 0014-2999
1879-0712
language eng
recordid cdi_proquest_miscellaneous_67735874
source MEDLINE; Elsevier ScienceDirect Journals
subjects Abdomen
Animals
Antineoplastic Agents - pharmacology
Antineoplastic Agents - therapeutic use
Biological and medical sciences
Carcinoma, Ehrlich Tumor - drug therapy
Carcinoma, Ehrlich Tumor - immunology
Carcinoma, Ehrlich Tumor - pathology
Cell Proliferation
Colony-Forming Units Assay
Dose-Response Relationship, Drug
Gastroenterology. Liver. Pancreas. Abdomen
Haematopoiesis
Hematopoietic Stem Cells - drug effects
Hematopoietic Stem Cells - pathology
Killer Cells, Natural - drug effects
Killer Cells, Natural - immunology
Male
Medical sciences
Mice
Mice, Inbred BALB C
Myelopoiesis - drug effects
Natural killer
Neoplasm Transplantation
Organometallic Compounds - pharmacology
Organometallic Compounds - therapeutic use
Other diseases. Semiology
Pharmacology. Drug treatments
Titanocene
Tumour
title Antitumour activity of [1,2-di(cyclopentadienyl)-1,2-di( p- N, N-dimethylaminophenyl)-ethanediyl] titanium dichloride in xenografted Ehrlich's ascites tumour
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T22%3A46%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Antitumour%20activity%20of%20%5B1,2-di(cyclopentadienyl)-1,2-di(%20p-%20N,%20N-dimethylaminophenyl)-ethanediyl%5D%20titanium%20dichloride%20in%20xenografted%20Ehrlich's%20ascites%20tumour&rft.jtitle=European%20journal%20of%20pharmacology&rft.au=Valadares,%20Marize%20C.&rft.date=2006-03-18&rft.volume=534&rft.issue=1&rft.spage=264&rft.epage=270&rft.pages=264-270&rft.issn=0014-2999&rft.eissn=1879-0712&rft.coden=EJPHAZ&rft_id=info:doi/10.1016/j.ejphar.2006.01.056&rft_dat=%3Cproquest_cross%3E67735874%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=67735874&rft_id=info:pmid/16513106&rft_els_id=S0014299906000884&rfr_iscdi=true